Announcements Trials
Browse Landscape

Status

Approved for marketing 1

Sponsor Class

INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

Breast 1

Conditions

Stomach Neoplasms 3Breast Neoplasms 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Recurrence 1Ovarian Neoplasms 1Neoplasm Metastasis 1Hematologic Neoplasms 1HER2-positive Breast Cancer 1Esophageal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Breast Cancer Metastatic 1

Interventions

Trastuzumab 14pertuzumab 10Docetaxel 9tucatinib 4Carboplatin 2Capecitabine 2Ado-Trastuzumab Emtansine 2trastuzumab deruxtecan 1pyrotinib 1margetuximab 1atezolizumab 1Paclitaxel 1Injections 1Hospital Information Systems 1Electronic Health Records 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × HER2-positive Breast Cancer × margetuximab × Clear all
NCT03133988 2025-02-14

Margetuximab Expanded Access Program

TerSera Therapeutics LLC

Approved for marketing
Breast

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡